Survival outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer patients
NACT patients have worse survival, compared with their ACT counterparts. Although patients with pCR after NACT derive significant survival benefits, NACT-disfavored subgroups may gain limited benefit from NACT, and alternative approaches should be considered.
Authors
- Purong Zhang (ORCID: https://orcid.org/0000-0003-4317-1355)
- Juecai Chen
- Junjie Li (ORCID: https://orcid.org/0000-0003-4510-8261)
- Chengshi Wang (ORCID: https://orcid.org/0000-0003-2947-7059)
- Xiaoyan Zhang (ORCID: https://orcid.org/0000-0001-5179-1488)
- Jianhui Zhang (ORCID: https://orcid.org/0000-0002-3053-3428)
- Songbo Zhang (ORCID: https://orcid.org/0009-0009-6233-2004)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1093/oncolo/oyaf356
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00